3‐Aryl‐substituted imidazopyridines as antituberculosis agents
Novel inhibitors are needed to tackle tuberculosis. Herein, we report the 3‐aryl‐substituted imidazo[1,2‐a]pyridines as potent antituberculosis agents. A small library of 3‐aryl‐substituted imidazo[1,2‐a]pyridines was synthesized using direct arylation, followed by nitro reduction and finally Pd‐cat...
Gespeichert in:
Veröffentlicht in: | Archiv der Pharmazie (Weinheim) 2021-10, Vol.354 (10) |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Novel inhibitors are needed to tackle tuberculosis. Herein, we report the 3‐aryl‐substituted imidazo[1,2‐a]pyridines as potent antituberculosis agents. A small library of 3‐aryl‐substituted imidazo[1,2‐a]pyridines was synthesized using direct arylation, followed by nitro reduction and finally Pd‐catalyzed C−N coupling reactions. The compounds thus obtained were evaluated against Mycobacterium tuberculosis H37Rv. Compound 26 was identified as an antituberculosis lead with a minimum inhibitory concentration of 2.3 μg/ml against M. tuberculosis H37Rv. This compound showed a selectivity index of 35. The docking of 26 in the active site of the M. tuberculosis cytochrome bc1 complex cytochrome b subunit (Mtb QcrB) revealed key π–π interactions of compound 26 with the Tyr389 and Trp312 residues of Mtb QcrB. |
---|---|
ISSN: | 0365-6233 1521-4184 |
DOI: | 10.1002/ardp.202000419 |